Clinical effect of bacterial lysate capsules combined with salmeterol on stable COPD
Objective To explore the clinical effect of bacterial lysate capsules combined with salmeterol on stable chronic obstructive pulmonary disease(COPD).Methods A total of 140 patients with stable COPD admitted in our hospital from October 2021 to November 2022 were selected and divided into control group and observation group by random number table method,with 70 cases in each group.The control group was treated with salmeterol,and the observation group was treated with bacterial lysate capsules on this basis.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was 97.14%,which was significantly higher than 88.57%in the control group(P<0.05).After treatment,the modified British Medical Research Council Dyspnea Scale(mMRC)score of the observation group was significantly lower than that of the control group(P<0.05).After treatment,CD3+,CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group,and CD8+ was significantly lower than that in the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ)and C-C motif chemokine ligand 16(CCL16)in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Bacterial lysate capsules combined with salmeterol is effective in the treatment of patients with stable COPD.It can improve the symptoms of dyspnea,reduce the level of inflammatory response,and enhance immune function with high safety,which is worth promoting.
万方数据
维普
